Proactive – Reneuron Group PLC’s Catherine Isted on the business model, cash runway and its two legacy products
04 August 2022: ReNeuron Group PLC’s chief executive-elect Catherine Isted joined Proactive to talk about her last ten months in the job, working to refine the strategic and operational focus of the company.
Proactive – Exosome tech delivers therapeutic proteins to hard to access region of brain
11 October 2021: ReNeuron Group’s Olav Hellebo joins Proactive to talk about their exosome technology which has shown it can deliver therapeutic proteins to a hard to access region of the human brain.
Share Talk – interview with Olav Hellebo
6 April 2021: Please click here to access the Share Talk website to hear the interview with Olav Hellebo, SEO of ReNeuron.
February 2021 – OHSU Research News: OHSU Casey Eye Institute grows gene and cell therapy research by performing its first stem cell therapy in the retina
To read the full article please click here.
January 2021 – Proactive Investors: ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy
July 2020 – Proactive Investors: ReNeuron’s Michael Hunt says key focus now is to build dataset for retinal disease study
June 2020 – Proactive Investors: ReNeuron’s Michael Hunt explains new emphasis on its retinal and exosome technology programmes
May 2020 – Proactive Investors: ReNeuron’s Michael Hunt talks new potential for its CTX therapy in treating Huntington’s disease
April 2020 – Proactive Investors: ReNeuron looking at applications of its own technology to deliver virus vaccine
February 2020 – Proactive Investors: ReNeuron’s retinal treatment ‘appears to have sustained long-term beneficial effect’